



Code No. FM-PVC-03

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

Date: June 2021

Update in dosing information with respect to food.

Dear Healthcare Professional,

It was noted that the dosing information (specifically the timing of dosing with respect to food) in the product information for the levodopa containing products was not optimal: it did not make clear that dosing without food is possible, and may be preferable for some patients. This update makes Levodopa dosing information with respect to food more consistent with other levodopa containing medicines and with most clinical guidance.

The MAH in agreement with the Egyptian Pharmaceutical Vigilance center (EPVC) would like to inform you of the following update:

The dosing of levodopa products should be as follow: – Where possible, Levodopa should be taken in-between meals, so that the competitive effect of dietary protein on levodopa can be avoided and to facilitate a more rapid onset of action. – A delay between a meal and Levodopa dosing may be advisable to avoid lower absorption of levodopa by food. – Undesirable gastrointestinal effects, which may occur mainly in the early stages of the treatment, can largely be controlled by taking Levodopa with a low protein snack or liquid or by increasing the dose slowly.

Please ensure awareness of the content of this letter within your team.

Call for reporting:

The Egyptian Pharmaceutical Vigilance Center is reminding HCP and public to report any safety information regarding human medicinal products including adverse drug reactions, medications errors, lack of efficacy and other medicine related problems through the following contacts:

Egyptian Pharmaceutical Vigilance Center:

Address: 21 Abd El Aziz Al Soud Street, El-Manial, Cairo, Egypt, And PO Box: 11451

Telephone: (+2)02 25354100, Extension: 1303 Fax: +202 – 23610497

Email: pv.followup@edaegypt.gov.eg

Online reporting: <http://www.eda.mohp.gov.eg>